Results for this period
Full year1 October 2025 to 30 September 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company strengthened consulting sales aimed at expanding clinic revenue through management transformation and focused on expanding sales centered on AI and voice-enabled electronic medical records.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025 to 30 September 2026 |
| Net Sales | ¥2,516 million (YoY +4.5%) |
| Operating profit | ¥568 million (YoY +3.5%) |
| Ordinary income | ¥726 million (YoY +11.4%) |
| Profit attributable to owners of the parent | ¥495 million (YoY +10.6%) |
| Net income per share | ¥222.40 |
| Operating Margin | 22.6% |
| Equity ratio | End of the current fiscal period 87.1% / End of previous period 88.9% |
| Total assets | ¥5,147 million |
| Net assets | ¥4,480 million |
| Cash flows from operating activities | ¥553 million |
| Cash flows from investing activities | ¥1,017 million |
| Cash flows from financing activities | ¥-206 million |
| Cash and cash equivalents at end of period | ¥2,467 million |
| Full-year earnings forecast | Net Sales ¥2,550 million (YoY +1.4%) / Operating profit ¥577 million (YoY +1.6%) / Ordinary income ¥727 million (YoY +0.1%) / Net income ¥497 million (YoY +0.5%) |
| Annual Dividend Forecast | 94 yen → 100 yen(+6.4%) |
| Payout ratio | 42.3% |
| Depreciation and amortization | ¥104,341 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets ¥3,833 thousand / Extraordinary loss Loss on disposal of fixed assets ¥0 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable items |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for individual investors) |
| Issued Shares at Period-End | 2,228,000 shares |
| Treasury Shares at Period-End | 165 shares |
| Factors Behind Changes in Business Performance | The company strengthened consulting sales aimed at expanding clinic revenue through management transformation and focused on expanding sales centered on AI and voice-enabled electronic medical records. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This resulted from strengthening consulting sales and focusing on expanding sales centered on AI and voice-enabled electronic medical records.